当前位置：
X-MOL 学术
›
Lancet Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Correction to Lancet Oncol 2024; 25: 1176–87
The Lancet Oncology ( IF 41.6 ) Pub Date : 2024-10-25 , DOI: 10.1016/s1470-2045(24)00626-0
The Lancet Oncology ( IF 41.6 ) Pub Date : 2024-10-25 , DOI: 10.1016/s1470-2045(24)00626-0
Vera P, Thureau S, Le Tinier F, et al. Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402): a multicentre, randomised, controlled phase 2 trial. Lancet Oncol 2024; 25: 1176–87—In this Article, Pierre Boissellier should have been spelled Pierre Boisselier. This correction has been made to the online version as of Oct 25, 2024.
更新日期：2024-10-26
京公网安备 11010802027423号